Company intelligence / Profile preview

Ocean Rock

Providence, Rhode Island, USAshop.oceanrockwellness.com ↗

Ownership: Private
Development stage: Other

Overview

Ocean Biomedical is advancing a pipeline of next-generation immunotherapies and vaccines. Its lead oncology program uses bispecific antibodies targeting PD-(L)1, VEGF, CHI3L1, and CTLA4 to overcome resistance in EGFR-mutant NSCLC and other cancers. Preclinical data show strong tumor suppression. In infectious diseases, its NIH-funded malaria vaccine program targets GARP using mRNA/lipid nanoparticle delivery; non-human primate studies are ongoing with expedited FDA guidance potentially enabling first-in-human trials by late 2025.

Therapeutic areas: Infectious DiseasesOncology
Modalities: Bispecific monoclonal antibodyMonoclonal antibodymRNA-based drugsVaccine
Industry: Biotech

Partnerships

NIH funding partnership for malaria researchcollaborations with leading academic researchers/institutions

Beyond the preview

Go deeper on Ocean Rock.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocean Rock.

Explore the full profile